IDH1 Mutation

9 registered clinical trials studyying IDH1 Mutation — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax NCT07471841	Timothy Pardee	Phase 2
Recruiting	Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Elig NCT06782542	Justin Watts, MD	Phase 2
Recruiting	Ivosidenib as Post-HSCT Maintenance for AML NCT06707493	Massachusetts General Hospital	Phase 2
Recruiting	Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML NCT06611839	Institute of Hematology & Blood Diseases Hospital, China	Phase 1 / Phase 2
Recruiting	Study of Olutasidenib and Temozolomide in HGG NCT06161974	Rigel Pharmaceuticals	Phase 2
Active Not Recruiting	Niraparib In Recurrent IDH 1/2 Gliomas NCT05406700	Massachusetts General Hospital	EARLY_Phase 1
Withdrawn	A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neopla NCT04955938	University of Chicago	Phase 1
Completed	Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors NCT04056910	Jason J. Luke, MD	Phase 2
Completed	BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations NCT03914742	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 1 / Phase 2